share_log

微創機器人-B：截至2023年12月31日止年度全年業績公告

MEDBOT-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

香港交易所 ·  Mar 27 10:53
Summary by Moomoo AI
上海微創醫療機器人（集團）股份有限公司（微創機器人）公佈截至2023年12月31日止年度全年業績。報告顯示，公司年內收入達人民幣104.6百萬元，較上年同期增長384.2%，主要得益於核心產品圖邁多科室應用獲批上市後市場強勁表現，以及骨科手術機器人在海外市場的成功推廣。然而，公司錄得淨虧損人民幣1,023.5百萬元，較上年的人民幣1,146.3百萬元有所改善，這主要由於營業收入增長帶來毛利增加，以及研發費用下降。公司自由現金流淨流出亦由上年的人民幣1,158百萬元下降42%至人民幣670百萬元。公司於報告期內無購買、出售或贖回任何上市證券，並遵守相關法律法規。董事會不建議派發末期股息。
上海微創醫療機器人（集團）股份有限公司（微創機器人）公佈截至2023年12月31日止年度全年業績。報告顯示，公司年內收入達人民幣104.6百萬元，較上年同期增長384.2%，主要得益於核心產品圖邁多科室應用獲批上市後市場強勁表現，以及骨科手術機器人在海外市場的成功推廣。然而，公司錄得淨虧損人民幣1,023.5百萬元，較上年的人民幣1,146.3百萬元有所改善，這主要由於營業收入增長帶來毛利增加，以及研發費用下降。公司自由現金流淨流出亦由上年的人民幣1,158百萬元下降42%至人民幣670百萬元。公司於報告期內無購買、出售或贖回任何上市證券，並遵守相關法律法規。董事會不建議派發末期股息。
Shanghai Micro-Chung Medical Robots (Group) Co., Ltd. (Micro-Chung Robots) announces its annual results for the year ended 31 December 2023. The report showed that the company's revenue for the year reached RMB104.6 million, an increase of 384.2% year-on-year, mainly due to the strong post-market performance of its core product Tomedo Medical Room applications, as well as the successful promotion of orthopedic surgery robots in overseas markets. However, the company recorded a net loss of RMB1,023.5 million, an improvement from RMB1,146.3 million a year earlier, mainly due to the increase in operating income led by an increase in gross profit and a decrease in R&D expenses. The Company's net free cash flow also decreased 42% to RMB670 million from RMB1,158 million a year earlier. The Company does not purchase, sell or redeem any listed securities during the reporting period and complies with relevant laws and regulations. The Board of Directors does not recommend the distribution of a final dividend.
Shanghai Micro-Chung Medical Robots (Group) Co., Ltd. (Micro-Chung Robots) announces its annual results for the year ended 31 December 2023. The report showed that the company's revenue for the year reached RMB104.6 million, an increase of 384.2% year-on-year, mainly due to the strong post-market performance of its core product Tomedo Medical Room applications, as well as the successful promotion of orthopedic surgery robots in overseas markets. However, the company recorded a net loss of RMB1,023.5 million, an improvement from RMB1,146.3 million a year earlier, mainly due to the increase in operating income led by an increase in gross profit and a decrease in R&D expenses. The Company's net free cash flow also decreased 42% to RMB670 million from RMB1,158 million a year earlier. The Company does not purchase, sell or redeem any listed securities during the reporting period and complies with relevant laws and regulations. The Board of Directors does not recommend the distribution of a final dividend.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more